Angiotensin II and Cardiovascular-Renal Remodelling in Hypertension: Insights from a Human Model Opposite to Hypertension

被引：9
作者：
Ravarotto V. [1 ]
Pagnin E. [1 ]
Fragasso A. [1 ]
Maiolino G. [1 ]
Calò L.A. [1 ]
机构：
[1] Department of Medicine, Nephrology and Hypertension, University of Padova, Via Giustiniani, 2, Padua
来源：
High Blood Pressure & Cardiovascular Prevention | 2015年 / 22卷 / 3期
关键词：
Angiotensin II signaling; Bartter’s syndrome; Cardiovascular-renal remodeling; Gitelman’s syndrome; Nitric oxide; Rho kinase;
D O I：
10.1007/s40292-015-0082-7
中图分类号：
学科分类号：
摘要：
Insights into the Angiotensin II (Ang II) signalling pathways have been provided by extensive studies using Bartter’s/Gitelman’s syndromes patients. These syndromes are characterized by activation of the renin-angiotensin-aldosterone system but do not develop hypertension and cardiovascular remodelling, therefore represent a mirror image of hypertension and clinically manifest themselves as the opposite of hypertension. The short and the long-term signalling of Ang II remain an important matter of investigation to shed light on mechanisms responsible for the pathophysiology of hypertension and its long-term complications, such as cardiovascular remodelling and atherogenesis. In particular the long-term signalling of Ang II is involved in the pathophysiology of cardiovascular-renal remodelling, inflammatory and hypertrophic responses in which the relationship between RhoA/Rho kinase pathway and NO system plays a crucial role. This review reports the results of our studies in Bartter’s and Gitelman’s syndromes to get better insight these processes and the role of Ang II signaling. The information obtained from the studies in Bartter’s/Gitelman’s patients can, in fact, clarify, confirm or be used to gather more general data on the biochemical mechanisms responsible for the pathophysiology of hypertension and its long-term complications and could contribute to identify additional potential significant targets of therapy. © 2015, Springer International Publishing Switzerland.
引用
收藏
页码：215 / 223
页数：8
相关论文
共 84 条
[1]  
Mehta P.K., Griendling K.K., Angiotensin II cell signaling. Physiological and pathological effects in the cardiovascular system, Am J Physiol Cell Physiol, 92, pp. 82-97, (2007)
[2]  
Nguyen Dinh Cat A., Touyz R.M., Cell signaling of angiotensin II on vascular tone: novel mechanisms, Curr Hypertens Rep, 13, pp. 122-128, (2011)
[3]  
Dzau V.J., Lopez-Ilasaca M., Searching for transcriptional regulators of Ang II induced vascular pathology, J Clin Invest, 115, pp. 2319-2322, (2005)
[4]  
Benigni A., Corna D., Zoja C., Sonzogni A., Latini R., Salio M., Conti S., Rottoli D., Longaretti L., Cassis P., Morigi M., Coffman T.M., Remuzzi G., Disruption of the Ang II type 1 receptor promotes longevity in mice, J Clin Invest, 119, pp. 524-530, (2009)
[5]  
Calo L., D'Angelo A., Cantaro S., Rizzolo M., Favaro S., Antonello A., Borsatti A., Intracellular calcium signalling and vascular reactivity in Bartter’s syndrome, Nephron, 72, pp. 570-573, (1996)
[6]  
Calo L.A., Schiavo S., Davis P.A., Pagnin E., Mormino P., D'Angelo A., Pessina A.C., Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension, J Hypertens, 28, pp. 111-118, (2010)
[7]  
Calo L.A., Davis P.A., Rossi G.P., Understanding the mechanisms of angiotensin II signaling involved in hypertension and its long-term sequelae: insights from Bartter’s and Gitelman’s syndromes, human models of endogenous angiotensin II signaling antagonism, J Hypertens, 32, pp. 2109-2119, (2014)
[8]  
Bartter F.C., Pronove P., Gill J.R., Maccardle R.C., Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis, Am J Med, 33, pp. 811-828, (1962)
[9]  
Naesens M., Steels P., Verberckmoes R., Vanrenterghem Y., Kuypers D., Bartter’s and Gitelman’s syndromes: From gene to clinic, Nephron Physiol, 96, pp. 65-78, (2004)
[10]  
Simon D.B., Karet F.E., Hamdan J.M., DiPietro A., Sanjad S.A., Lifton R.P., Bartter’s syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na–K–2Cl cotransporter NKCC2, Nat Genet, 13, pp. 183-188, (1996)
123456789